Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer
A phase 3 trial of Pertuzumab in HER2-positive breast cancer, run by Biocad, active and no longer recruiting.
Overview
Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer is a phase 3 interventional study registered as NCT05802225 by Biocad, with 398 participants enrolled, started 2023-01-30 and due to reach its primary completion in 2025-06-06. Interventions recorded: BCD-178 and Perjeta.
Similar pages
not linked directly; found by shared links- TrialAn Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed/Refractory Multiple Myeloma
Shares Biocad and the tag pipeline.
- TrialBCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer
Shares Biocad and the tag pipeline.
- TrialA Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer
Shares Pertuzumab, HER2-positive breast cancer and the tag pipeline.
- TrialStudy of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation
Shares Pertuzumab, HER2-positive breast cancer and the tag pipeline.
- TrialTreatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel
Shares Pertuzumab and the tag pipeline.
- TrialDV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer
Shares Pertuzumab, HER2-positive breast cancer and the tag pipeline.
- TreatmentBCD-100
Shares Biocad and the tag pipeline.
- TrialA Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer
Shares Pertuzumab, HER2-positive breast cancer and the tag pipeline.